[ad_1]
A third kind of heart failure treatment – not Valsartan or Losartan – has been reviewed for cancer too much.
One lot of Irbesartan and seven lots of Irbesartan HCTZ, both made in China by Zhejiang Huahai Pharmaceuticals, have been recalled by Prinston Pharmaceuticals company, Solco Healthcare. As with the funeral parade of Valsartan and Losartan recalls since July, the amount of N-nitrosodiethylamine (NDEA) exceeds the FDA's daily standards. The International Agency for Cancer Resarch clbadifies NDEA as a "probable human carcinogen."
The company-written, FDA-posted recalls the advice of patients to consult their doctor or pharmacist.
Recalled lots are:
Digital Access for only $ 0.99
For the most comprehensive local coverage, subscribe today.
▪ Irbesartan 300mg, 90-count, lot No. 331B18009, expiration 2/2021.
▪ Irbesartan HCTZ 300mg / 12.5mg, 30-count, lot Nos. 327A18001 and 327A18001, expiration 03/2021.
▪ Irbesartan HCTZ 300mg / 12.5mg, 90-count, lot Nos. 327B18008 and 327B18009, expiration 03/2021.
▪ Irbesartan HCTZ 150mg / 12.5mg, 30-count, lot Nos. 325D18004 and 325D18005, expiration 03/2021.
▪ Irbesartan HCTZ 150mg / 12.5mg, 90-count, lot Nos. 325B18004, expiration 03/2021.
Consumers with questions should contact their pharmacist, doctor or email Solco at [email protected].
[ad_2]
Source link
